^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    clesitamig (RG6524)

    i
    Other names: RG6524, RO7616789, ALPS12, ALPS 12, RG 6524, RO 7616789, ALPS-12, RG-6524, RO-7616789
    Associations

    News

    Trials
    Company:
    Roche
    Drug class:
    CD3 agonist, CD137 agonist, DLL3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    10d
    A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER (clinicaltrials.gov)
    P1, N=122, Recruiting, Chugai Pharmaceutical | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Gazyva (obinutuzumab) • clesitamig (RG6524)
    4ms
    A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER (clinicaltrials.gov)
    P1, N=122, Not yet recruiting, Chugai Pharmaceutical
    New P1 trial
    |
    Gazyva (obinutuzumab) • clesitamig (RG6524)
    9ms
    A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas (clinicaltrials.gov)
    P1, N=41, Completed, Hoffmann-La Roche | Recruiting --> Completed | N=168 --> 41 | Trial completion date: Sep 2025 --> Mar 2025 | Trial primary completion date: Sep 2025 --> Mar 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Actemra IV (tocilizumab) • clesitamig (RG6524)
    over2years
    A DLL3/CD3/CD137 trispecific T cell engager shows potent antitumor activity in small cell lung cancer models (AACR 2023)
    We therefore developed a DLL3/CD3/CD137 trispecific T cell engager composed of two CD3/CD137 dual specific Fabs and one extra DLL3 Fab (DLL3 trispecific, RG6524). We initially investigated the CD3 and CD137 signal transduction in Jurkat cells harboring NFAT or NF-κB reporter cocultured with DLL3 positive cells...Likewise, tocilizumab treatment did not reduce the efficacy, suggesting that CRS mitigation did not abrogate the therapeutic benefit.We finally assessed the tolerability in non-human primates. Our data showed that DLL3 trispecific has potent activity and is well suited for clinical application in SCLC. These findings provide a rationale for the clinical testing of DLL3 trispecific.
    Preclinical • IO biomarker • Trispecific
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • DLL3 (Delta Like Canonical Notch Ligand 3) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    DLL3 positive
    |
    Actemra IV (tocilizumab) • clesitamig (RG6524)